An expert discusses how decision-making for minimally invasive benign prostatic hyperplasia (BPH) therapies has evolved over the past decade to position these treatments earlier in the algorithm (sometimes before long-term medication), emphasizing shared decision-making that considers patient factors such as age, desire to preserve sexual function, medication adherence, and lifestyle preferences rather than following a rigid treatment sequence.
An expert discusses how the current benign prostatic hyperplasia (BPH) treatment landscape is dominated by traditional approaches such as watchful waiting and medical therapy (particularly α-blockers as first-line treatment). However, minimally invasive therapies such as prostatic urethral lift, water vapor therapy, and temporary stents have emerged over the past decade as office-based options that bridge the gap between lifelong medications and more invasive surgeries while preserving sexual function.
Krambeck pointed to the growing importance of medical management in stone disease prevention.
Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, highlighted how bpMRI aligns with evolving diagnostic strategies.
Mihir S. Shah, MD, outlines ongoing research on treatment intensification prior to radical prostatectomy in patients with localized prostate cancer.
Apolo also discusses the potential role of ctDNA in the bladder cancer space.
Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available.
A. Lenore Ackerman, MD, PhD, outlines what the data suggest about non-antibiotic approaches for UTI prophylaxis, as well as how these options should be positioned when counseling patients.
Timothy Daskivich, MD, MSHPM, noted that guidelines are central to shaping physician behavior and strongly influence clinical practice
Veda Giri, MD, outlines points of consensus and areas of disagreement across national and international guideline recommendations for germline testing in prostate cancer.
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC.
Ensuring consistent diagnostic quality remains critical.
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care.
Sia Daneshmand, MD, discusses evolving care strategies after enfortumab vedotin plus pembrolizumab in bladder cancer.
A Lenore Ackerman, MD, discusses a recent guideline amendment that places a greater value on a negative urinalysis in ruling out UTI.
Margaret A. Knoedler, MD, discusses her experience using the Reverse Deflection CVAC System.
Fosnight emphasizes that the cycle of shame, secrecy, and loneliness compounds the burden of urinary incontinence far beyond its physical effects.
Veda Giri, MD, highlights her recent review publication on the current state of germline testing in prostate cancer.
Jane T. Kurtzman, MD, underscores the collaborative role of urologists and trauma surgeons in addressing this issue.
John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.
A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women.
Manuj Agarwal, MD, discusses which patients may be best suited for prostate brachytherapy.
Among men without prostate cancer at baseline, healthier dietary patterns appeared somewhat protective.
Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies.
William C. Huang, MD, discusses data on mitomycin for intravesical solution from the pivotal ENVISION trial and the OPTIMA II study.
Both experts agreed that although the details shift by condition, the core structure of patient-centered decision-making remains constant.
Kevin Koo, MD, MPH, discusses the implications of a digital stone measurement tool for clinical care.
Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy.
William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial.
Kurtzman stressed that it is difficult to disentangle whether the increased hypertension risk is primarily due to the intervention itself or to the patients’ initial clinical state.
